Is Danaher (DHR) overvalued or fairly valued?

MarketChacha shows Danaher's valuation in context — a forward P/E of about 21.7, a price-to-book of about 2.7 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is the share price of Danaher (DHR)?

Danaher last traded at $201.11 (-1.3% on the day), as of 7/20/2026 — a delayed quote shown for education, not investment advice.

Danaher

DHR · NYSE · Life Sciences · United States

$201.11-1.3%

Delayed · as reported by Yahoo Finance · as of Jul 20, 2026, 8:00 PM

Snapshot

TickerDHR

ExchangeNYSE

SectorLife Sciences

IndustryDiagnostics & Research

CountryUnited States

Employees58,000

HeadquartersWashington, United States

Market cap$142.3B

P/B2.7

Volume6.08M

Websitewww.danaher.com

Filings tracked0

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

Profile as reported by Yahoo Finance.

Who owns it

Insiders10.7%
Institutions84.5%
Public & other4.8%

2,900 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.7.30%
Vanguard Capital Management LLC5.81%
State Street Corporation3.94%
FMR, LLC3.18%
JPMORGAN CHASE & CO2.39%
Price (T.Rowe) Associates Inc2.17%
Wellington Management Group, LLP2.09%
Geode Capital Management, LLC2.00%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

What's expected next

Next quarter

Rev $6.5B · EPS 2.05

Est. earnings growth +8.6%

Next fiscal year

Rev $28.4B · EPS 9.24

Est. earnings growth +8.6%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$160.9352-wk range$242.80

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Ask MarketChacha about DHR

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.